Over the last year or so we have seen a marked change in the treatment landscape for men with castrate resistant advanced prostate cancer. The FDA has approved sipuleucel-T (Provenge), cabazitaxel (Jevtana) and last week it also approved abiraterone (Zytiga). This changed landscape of multiple treatment options creates new problems, of course good problems. Prostate [...]
If you read my previous post ,you will see Senator McCain’s plan to eliminate the Prostate Cancer Research Program within the Congressionally Directed Medical Research Program (CDMRP). The loss of this program could shorten many of our lives and add significantly to our pain and suffering. Now is the time to work with the rest of [...]
Researchers wanted to determine if concurrent the development of morbidity issues ( i.e.- myocardial infarction, congestive heart failure, angina, diabetes, stroke, circulation problems, inflammatory bowel disease, or amputation) is associated with treatment regret among men with PSA recurrence following failed primary therapy for prostate cancer. The researchers evaluated 795 men from the Comprehensive, Observational, Multicenter, [...]
Patient advocates have long raised the question about the wisdom in using hormone therapy for extended periods of time. The introduction of intermittent scheduling of hormone therapy (ADT) has become more acceptable thanks to the questions raised by the community and the support of some oncologists who have been willing to think out of the [...]
Whether you are struggling with advanced prostate cancer, or a member of your family is, we all know how this journey can be very difficult. As we look forward to this New Year, 2011, we can be sure that there will be many difficult and down periods, but we should also remember there will also [...]